Compare Abeona Therapeutics Inc (ABEO) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Lucid Group Inc — how do they compare? Abeona Therapeutics Inc trades at $7.49 (market cap $421.19M), while Lucid Group Inc trades at $6.7 (market cap $2.64B). The key difference: Lucid Group Inc is far larger — about 6.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | LCID | |
|---|---|---|
Market Cap | $421.19M | $2.64B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $24.77 |
52-Week Low | $4.17 | $4.62 |
Enterprise Value | $276.10M | $5.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lucid Group (LCID) trades at $6.61, down 6.11% amid ongoing operational challenges. The stock shows bearish technical signals with negative moving averages and faces fundamental headwinds including consistent quarterly losses, negative profit margins, and substantial cash burn. Recent news highlights an operational reset targeting $1.4 billion in cash improvements and delays to the affordable Cosmos EV launch to 2027.
The outlook remains challenging with deep losses and cash burn overshadowing revenue growth. Analyst consensus is cautious with 67% hold ratings, though the $10.50 price target suggests potential upside. Key risks include execution of turnaround plans, intense EV competition, and funding needs. The stock's direction hinges on successful cost reductions and future product execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
